A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The ...

Heart attacks remain a significant health concern in the United States. According to the Centers for Disease Control and ...

Gold dust in eyes might seem like an unusual therapy – but a new mouse study in the US shows the approach could potentially ...

The complete response letter did not identify any issues with the safety or efficacy of Eylea HD, Regeneron officials said.

There are adaptations and tools to help deal with low-vision issues that can result from aging and other conditions.

Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

Regeneron aims for FDA approval of extended dosing for EYLEA HD in AMD and DME, with a decision by April 2025. Pre-filled ...

If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.

Regeneron (REGN) announces FDA review of sBLA for Eylea HD to treat macular edema and expand dosing. Read more here.

A new study shows that gold nanoparticles injected into the retina can restore vision in mice with retinal degeneration, offering a less invasive alternative to current retinal prostheses.